Expert: Professor Susan Branford Head, Leukemia Unit, Genetics and Molecular Pathology, SA Pathology, Adelaide (Australia)

Program:
Overview of significant biological aspects presented during the meeting, including:

• BCR::ABL1 protein degraders (01:23)
  • Abstract 4157: Targeting CML with potent and specific BCR::ABL1 degraders (Cruz-Rodriguez N et al.)
  • Abstract 1387: An orally active pan-BCR::ABL1 degrader Tgrx-3247 potentially targets a wide spectrum of orthosteric, allosteric and compound mutations resistant to TKI therapies (Wang Y et al.)
• Novel biomarkers of treatment-free remission (06:41)
  • Abstract 993: Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission (Ross D et al.) 
• Blood cancer-related gene variants at diagnosis and treatment outcome (09:23)
  • Abstract 991: Strong association between cancer gene variants at diagnosis, especially ASXL1, and emergence of kinase domain mutation-driven resistance in CML patients despite frontline treatment with more potent BCR::ABL inhibitors (Shanmunagathan N et al.)
  • Abstract 1774: The combination of asciminib with ATP competing TKIs might overcome the negative impact of ASXL1 mutations on molecular response in newly diagnosed CML patients (Ernst T et al.)

• Questions and Answers (Clinical and biological) (18:00)

If you have any questions or comments to the speaker, please email info@cml-foundation.org.